drugset / Trial / NCT04186403
Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study evaluates the safety and tolerability of brexpiprazole in the treatment of adults with borderline personality disorder.
Timeline
- Start
- 2020-01-13
- Primary completion
- 2021-09-22
- Completion
- 2021-09-22
Outcome
Missed primary endpoint
paper The primary endpoint of the randomised study was not met. PMID 39558901 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brexpiprazole | Small molecule | 2 mg | Oral |
| Subject | Brexpiprazole | Small molecule | 3 mg | Oral |